Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Like the look of this. Let’s hope they dont go about things the way HE1 did and have better luck on initial drilling. HE1 listed with 496,893,111 shares and now have 3,715,710,763 shares in issue. Hopefully HEX can get to the same point of flowing Helium with far less dilution.
High risk high reward and a lot of funding required.
It’s not how many I sold Tech. It’s that I believed the previous RNS releases suggesting that the “ next steps are to finalise standard production and operating protocols and to commence clinical trials that should lead to an accredited Laboratory Developed (LDT) test for launch initially in the USA” When clearly they’ve been spinning plates
You’ve no idea how many I sold or still hold Tech.
I might be “bloody minded” but I’m not trying to defend the indefensible nor am I making deliberately overly positive assumptions about what the placing funds will or will not be spent on, which could mislead.
RE "Neil, why was BIO needed...."
Dead simple - in the same way that my customers structure a deal with my company. They don't want the hassle of going to supplier A for this part, supplier B for this part, supplier C for the design, supplier D for testing.
What’s that got to do with signing an agreement for 15% Royalties with CorePath and now 10% with BIO. A company set up by Mr Behnke in February this year ?
Do you think if E3 Fund were happy to provide the £500k drawdown there would have been a placing? Do you think the interview posted 16 minutes after the release of the Placing RNS was the behaviour of a Professional and reputable company? Do you think the interview was Professional ? Do you think the interviewer was professional in their preparation and questions they asked?
Is that the sort of way you would conduct yourself in your business ?
RNS Number : 5257K - 06 May 2022 - Heads of terms signed with CorePath Laboratories, USA,
"CorePath is a specialist oncology reference laboratory bringing together leading clinicians, scientists, academic affiliates and state of the art facilities and will be responsible for all activities in the USA including development, clinical trials and test validation for clinical use"
RNS Number : 8949I - 02 April 2024 - Licensing and Partnership MoU for North America
"BIO intends to fully fund all expenditure on development, clinical trials, accreditation and marketing of diagnostic tests for the CIZ1B Biomarker in North America which would represent a significant saving on current planned expenditure by the Company"
""No thanks from Corepath? I don't understand that statement. Neil"
Neil can you explain why you think BIO was needed given the Heads of Terms with CorePath which clearly states as above
CorePath "will be responsible for all activities in the USA including development, clinical trials and test validation for clinical use" ?
Why was there a need for Mr Behnke set up BIO and why have CIZ signed the MoU for annual royalty fees of 10% of net sales instead of the "Proposed 15% royalty and royalty sharing arrangements for the Company over all offering of products and services using CIZ1B via CorePath in the USA" ?
neil you are relentless.
they haven't even announced they've got the optimised mabs let alone a working high throughput ciz1b blood test for lung cancer and your pumping out this "the fact we don't need it now to fund the clinical trials means it will all be put to further work, re the development of other cancer detection."
unbelievable like that pathetic ************* attempt at pumping the share price to let the placees exit.
amateur placing forced on them because the agreed finance with e3 fund wasn't forthcoming. seriously underestimated pi holdings and completely taken pi's for granted and treated them in a disgusting manner.
bio was set up by mr behnke at his house with a doctor also involved. trying to make it out as anything else is derisory and misleading.
key word dependent - "bio's ability to meet its financial obligations is dependant on a group of sophisticated high net worth investors in the usa."
how big is the group of sophisticated hnwi's ? will they be impressed enough to part with their cash and invest in bio. currently a company set up at his home address with a doctor friend on the board.
keep pumping. be lucky.
"This is also consistent with the findings of another study that suggested that the predictive ability of a PRS was greater in younger individuals and optimally used to identify patients with borderline and intermediate clinical risk who should initiate statin therapy and intensify their lifestyle modification efforts "
Extract
"Importantly, all 12 SNPs are associated with CHD and are independent of classic risk factors (i.e., low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood pressure, smoking and diabetes mellitus), which is not the case for most of the SNPs included in genome-wide PRSs. The CARDIO inCode-Score® CHD PRS has been developed by GENinCode Plc for clinical use in a primary preventive setting and is commercially available in Europe. It has been shown to improve risk reclassification in a multi-ethnic population particularly at intermediate ASCVD risk, when including the PRS in the Framingham risk function [12,13]. In the secondary preventive setting, it has been associated with a higher risk of recurrence in patients with a first myocardial infarction [19,20]. CARDIO inCode-Score® is a ‘first in class’ PRS and has recently been granted De Novo status by the FDA and is currently progressing through to regulatory approval."
Is it agents or financiers holding the sale back ?